Home > Clinical Trials
Check All Search

Saved trials

ACTIVE_NOT_RECRUITING
NCT05480384
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
1 Enrollment(s)
2 Study location(s)
INTERVENTIONAL (PHASE2)
Esophageal Adenocarcinoma


Esophageal Cancer


HER-2 Protein Overexpression


Gastroesophageal-junction Cancer
RECRUITING
NCT07340164
Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy
116 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Ovarian Cancer
Ovarian Carcinoma, Recurrent
Ovarian Cancer Metastatic Recurrent
Ovarian Cancer (OvCa)
TERMINATED
NCT04593784
Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults
41 Enrollment(s)
3 Study location(s)
INTERVENTIONAL (PHASE2)
Healthy
RECRUITING
NCT07537673
Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Trastuzumab Deruxtecan
25 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Nausea and Vomiting Caused by Trastuzumab Deruxtecan
COMPLETED
NCT07529613
Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma
30 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Gastric Adenocarcinoma


Gastroesophageal Junction Adenocarcinoma
RECRUITING
NCT06610825
Castrate Resistant Prostate Cancer Enhertu Therapy
60 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Prostate Cancer Metastatic


Prostate Cancer


CRPC
RECRUITING
NCT04686305
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
304 Enrollment(s)
91 Study location(s)
INTERVENTIONAL (PHASE1)
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
ACTIVE_NOT_RECRUITING
NCT05034887
Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma
64 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Gastric Adenocarcinoma


Gastroesophageal Junction Adenocarcinoma